|Bid||62.54 x 800|
|Ask||62.40 x 800|
|Day's range||61.42 - 62.60|
|52-week range||60.71 - 86.29|
|Beta (5Y monthly)||0.72|
|PE ratio (TTM)||43.13|
|Earnings date||31 Jul 2023 - 04 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||82.24|
WILMINGTON, Del., May 25, 2023--Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
WILMINGTON, Del., May 08, 2023--Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
The news comes after Bloomberg reported that the bank has been weighing a range of strategic options amid concerns about its financial health.
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) delivered earnings and revenue surprises of -56.47% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Del., May 02, 2023--Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
WILMINGTON, Del., May 01, 2023--SCRATCH-AD Trial Demonstrates Substantial, Rapid Itch Reduction in Mild-Moderate Atopic Dermatitis Patients Treated with Opzelura (ruxolitinib) Cream
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
WILMINGTON, Del., April 20, 2023--European Commission Approves Opzelura (ruxolitinib) Cream asTreatment for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
WILMINGTON, Del., April 18, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May:
BOSTON & WILMINGTON, Del., April 16, 2023--5-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
WILMINGTON, Del., April 11, 2023--Incyte to Report First Quarter Financial Results
Incyte (INCY) shares are down 9.6% in the year so far on pipeline setbacks.
Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.
Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.
WILMINGTON, Del. & TOKYO, March 27, 2023--Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
WILMINGTON, Del., March 24, 2023--Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets